U.S. Markets closed

Bio-Rad Laboratories, Inc. (BIO)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
220.98-0.43 (-0.19%)
At close: 4:02PM EDT
People also watch
BRKRQGENCRLWATPKI

Bio-Rad Laboratories, Inc.

1000 Alfred Nobel Drive
Hercules, CA 94547
United States
510-724-7000
http://www.bio-rad.com

SectorHealthcare
IndustryMedical Laboratories & Research
Full Time Employees8,250

Key Executives

NameTitlePayExercisedAge
Mr. Norman D. SchwartzChairman, Chief Exec. Officer and Pres1.66MN/A67
Ms. Christine A. TsingosChief Financial Officer and Exec. VP610.17k219.87k58
Mr. John GoetzChief Operating Officer and Exec. VP1.12MN/A67
Mr. John HertiaExec. VP and Pres of Clinical Diagnostics Group688.21kN/A61
Mr. Michael CrowleyExec. VP of Global Commercial Operations581.4kN/A55
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products include reagents, instruments, and software which address specific niches within the in vitro diagnostics (IVD) test market. This segment sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. It operates in Europe, Pacific Rim, the United States, and internationally. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Corporate Governance

Bio-Rad Laboratories, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 8. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 6; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.